HIV Therapeutics, Biochemistry of
Published Online: 15 SEP 2006
Copyright © 2006 Wiley-VCH Verlag GmbH & Co. KGaA
Encyclopedia of Molecular Cell Biology and Molecular Medicine
How to Cite
Dayam, R. and Neamati, N. 2006. HIV Therapeutics, Biochemistry of. Encyclopedia of Molecular Cell Biology and Molecular Medicine. .
- Published Online: 15 SEP 2006
Although significant progress has been made in the treatment of HIV infection, we are still far from wining the battle. The combination of highly active antiretroviral therapy (HAART) in compliant patients comes close to stopping virus evolution; however, eradication of the infection has not been achieved because of the persistence of latent HIV-1 in resting memory CD4+ T cells. Moreover, several factors including the emergence of multidrug-resistant HIV strains, drug toxicity, the patient's ability to adhere to the prescribed therapy, and expensive medication have necessitated a reason to develop novel drugs and novel approaches to combat HIV infection.
Currently, the HAART regimen consists of nucleoside and nonnucleoside reverse transcriptase (RT) combined with protease (PR) inhibitors. This article summarizes all currently approved drugs for HIV-1 infection as well as drugs that have made significant progress in clinical trials but have not yet been approved. Where appropriate, their mechanism of action, mechanism of resistance, and toxicity are discussed
- Multidrug-resistant HIV Strain;
- Allosteric Binding Site;
- Transition State;
- Cytochrome P-450